SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 5, 2007, Pages 266-275

  Ashkan, Keyoumars ^a,b   A Wallace, Bradley ^a,c   Mitrofanis, John ^a,d   Pollo, Claudio ^e   Brard, Pierre Yves ^a   Fagret, Daniel ^a   Benabid, Alim Louis ^a  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

MPTP; Parkinson's disease; Parkinsonism; SPECT

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NISSL SUBSTANCE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; VALIDATION STUDY;

EID: 34347231269     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.10.009     Document Type: Article

References (48)

1. Piallat B., Benazzouz A., and Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8 (1996) 1408-1414
2. Piallat B., Benazzouz A., and Benabid A.L. Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. J Neural Transm Suppl 55 (1999) 71-77
3. Lange K.W., Loschmann P.A., Sofic E., Burg M., Horowski R., Kalveram K.T., et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol 348 (1993) 586-592
4. Benazzouz A., Boraud T., Dubedat P., Boireau A., Stutzmann J.M., and Gross C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284 (1995) 299-307
5. Moussaoui S., Obinu M.C., Daniel N., Reibaud M., Blanchard V., and Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 166 (2000) 235-245
6. Poewe W., and Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 18 Suppl 7 (2003) S16-S21
7. Varrone A., Marek K.L., Jennings D., Innis R.B., and Seibyl J.P. [(1 2 3)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 16 (2001) 1023-1032
8. Seibyl J., Jennings D., Tabamo R., and Marek K. Neuroimaging trials of Parkinson's disease progression. J Neurol 251 Suppl 7 (2004) vII9-vII13
9. Seibyl J.P. Imaging studies in movement disorders. Semin Nucl Med 33 (2003) 105-113
10. Morrish P.K. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?. Mov Disord 18 Suppl 7 (2003) S63-S70
11. Burn D.J., and O'Brien J.T. Use of functional imaging in Parkinsonism and dementia. Mov Disord 18 Suppl 6 (2003) S88-S95
12. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34 (1993) 331-338
13. Blanchet P.J., Konitsiotis S., Hyland K., Arnold L.A., Pettigrew K.D., and Chase T.N. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp Neurol 153 (1998) 214-222
14. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., et al. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 185 (2004) 272-280
15. Paxinos G., Huang X.F., and Toga A.W. The rhesus monkey brain in stereotaxic coordinates (2000), Academic Press, San Diego
16. Heise C.E., Teo Z.C., Wallace B.A., Ashkan K., Benabid A.L., and Mitrofanis J. Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?. Anat Embryol (Berl) 210 (2005) 287-302
17. Mitrofanis J. Calbindin immunoreactivity in a subset of cat thalamic reticular neurons. J Neurocytol 21 (1992) 495-505
18. Pahwa R., Wilkinson S.B., Overman J., and Lyons K.E. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 99 (2003) 71-77
19. Marek K.L., Seibyl J.P., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Fussell B., et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 (1996) 231-237
20. Asenbaum S., Pirker W., Angelberger P., Bencsits G., Pruckmayer M., and Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 105 (1998) 1213-1228
21. Benamer T.S., Patterson J., Grosset D.G., Booij J., de Bruin K., van Royen E., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15 (2000) 503-510
22. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., and Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 (1998) 314-319
23. Staffen W., Mair A., Unterrainer J., Trinka E., and Ladurner G. Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT. J Neural Transm 107 (2000) 543-552
24. Morrish P.K., Sawle G.V., and Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119 Pt 2 (1996) 585-591
25. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
26. Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M., et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 17 (2002) 45-53
27. Chouker M., Tatsch K., Linke R., Pogarell O., Hahn K., and Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 22 (2001) 721-725
28. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 (1995) 589-598
29. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J Am Med Assoc 287 (2002) 1653-1661
30. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 56 (1999) 529-535
31. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 (1979) 249-254
32. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
33. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80 (1983) 4546-4550
34. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292 (1984) 390-394
35. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50 (1984) 85-90
36. Dawson T.M. New animal models for Parkinson's disease. Cell 101 (2000) 115-118
37. Kitamura Y., Shimohama S., Akaike A., and Taniguchi T. The parkinsonian models: invertebrates to mammals. Jpn J Pharmacol 84 (2000) 237-243
38. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2 (2001) 325-334
39. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
40. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
41. Greenamyre J.T., Betarbet R., and Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9 Suppl 2 (2003) S59-S64
42. Marsden C.D., and Jenner P.G. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Ciba Found Symp 126 (1987) 239-256
43. Imbert C., Bezard E., Guitraud S., Boraud T., and Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 96 (2000) 71-76
44. Ohye C., Shibazaki T., Hirai T., Wada H., Kawashima Y., Hirato M., et al. A special role of the parvocellular red nucleus in lesion-induced spontaneous tremor in monkeys. Behav Brain Res 28 (1988) 241-243
45. Larochelle L., Bedard P., Boucher R., and Poirier L.J. The rubro-olivo-cerebello-rubral loop and postural tremor in the monkey. J Neurol Sci 11 (1970) 53-64
46. Fischman A.J., Babich J.W., Elmaleh D.R., Barrow S.A., Meltzer P., Hanson R.N., et al. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J Nucl Med 38 (1997) 144-150
47. Andringa G., Drukarch B., Bol J.G., de Bruin K., Sorman K., Habraken J.B., et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. Neuroimage 26 (2005) 1150-1158
48. Thobois S., Jahanshahi M., Pinto S., Frackowiak R., and Limousin-Dowsey P. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 23 (2004) 1-16